Walleye Capital
ADCT icon

Walleye Capital’s ADC Therapeutics ADCT Stock Holding History

Walleye Capital’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-77,390
Closed -$290K – 4679
2026
Q1 		$290K Buy
+77,390
New +$305K ﹤0.01% 3086
2025
Q4 		– Sell
-177,032
Closed -$708K – 4495
2025
Q3 		$708K Buy
+177,032
New +$558K ﹤0.01% 2347
2023
Q1 		– Sell
-513,618
Closed -$1.97M – 3873
2022
Q4 		$1.97M Sell
513,618
-182,645
-26% -$730K 0.04% 588
2022
Q3 		$3.36M Sell
696,263
-192,437
-22% -$1.39M 0.06% 328
2022
Q2 		$7.07M Buy
888,700
+640,346
+258% +$6.06M 0.19% 111
2022
Q1 		$3.65M Buy
248,354
+202,876
+446% +$3.22M 0.1% 221
2021
Q4 		$919K Buy
+45,478
New +$1.1M 0.03% 642

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Walleye Capital's ADCT Position: Q2 2026 in Review

Walleye Capital sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 77,390 shares — an estimated $290K sold.

Walleye Capital first reported a position in ADCT in Q4 2021 and held it in 7 quarters. The position peaked at $7.07M in Q2 2022. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Walleye Capital reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 77,390 ADC Therapeutics shares in Q2 2026, an estimated $290K.
  • Walleye Capital first reported a position in ADC Therapeutics in Q4 2021 and held it in 7 quarters.
  • Walleye Capital's ADC Therapeutics position peaked at $7.07M in Q2 2022.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.